Accordingly, the relative proportions of CD4 and CD8 effector T cells were elevated within the TNFi-treated RA patients of our study, a finding which might partially explain the differences in the relative proportions of memory and TEMRA cells between the csDMARD-only and the TNFi-treated patients. The gene discussed is CD4; the disease is rheumatoid arthritis.